Purpose: The purpose of this study was to evaluate outcomes of Descemet's stripping automated endothelial keratoplasty (DSAEK) using anterior stromal flawed (ASF) donor corneas that were unsuitable for use in full-thickness penetrating keratoplasty as a result of stromal scars, pterygia, or previous corneal refractive surgery and to compare results with DSAEK using standard tissue.
INTRODUCTION
Penetrating keratoplasty (PK) is a time-tested and effective surgical procedure used to treat vision loss resulting from diseases affecting any or all layers of the cornea. Because this surgery involves replacement of the host cornea with a full-thickness central corneal donor button, the Eye Bank Association of America's (EBAA) Medical Advisory Board has established criteria to ensure the quality of donor tissue used in PK. The criteria excludes the use of corneas with central scarring, pterygia within the central optical area of the cornea, evidence of ectasias, and also those having undergone corneal refractive surgeries for use in standard full thickness PK because these ocular histories may affect the optical outcome of the corneal recipient. 1 Penetrating keratoplasty is presently the standard of care for treatment of corneas with anterior stromal scarring and advanced ectasias; however, endothelial keratoplasty (EK) is viewed by many as the new standard of care for treatment of corneal endothelial failure. [2] [3] [4] The field of corneal transplantation has undergone significant advancements in the treatment of endothelial failure, most notably since 1998, when Gerrit Melles first described his method of replacing the posterior corneal surface using only the posterior portion of the donor tissue, which he named posterior lamellar keratoplasty. 5 Endothelial keratoplasty was again modified and further developed, initially as deep lamellar endothelial keratoplasty surgery by Terry 6, 7 and then as Descemet's stripping endothelial keratoplasty surgery by Price. 8, 9 The procedure was then renamed Descemet's stripping automated endothelial keratoplasty (DSAEK) by Gorovoy to distinguish the use of a microkeratome to prepare the donor tissue. 10 The DSAEK procedure is continuing to evolve as more data are presented and techniques are refined. 2, [11] [12] [13] [14] [15] [16] [17] [18] [19] Soon after the popularization of endothelial keratoplasty for treatment of corneal diseases involving the endothelium, it became clear that anterior stromal flawed (ASF) tissue unsuitable for PK because of anterior scarring, central pterygia, or previous corneal refractive surgery, but which still had excellent endothelium, might effectively be used in EK surgery. Therefore, in 2005, the medical advisory board to the EBAA revised the standard to allow the use of tissue with good endothelial cell densities but with anterior pathology to be transplanted in EK surgery. 1 We have designated this tissue in our eye bank as ASF. The criteria of acceptable tissue was therefore broadened by the EBAA to use additional tissue that would otherwise be unsuitable for PK as a recognition of the perceived value and usefulness of using only the healthy posterior portion of tissue that would otherwise be wasted. With some foresight, it was also recognized that with an aging population, the number of patients requiring corneal transplants will rise while simultaneously, the corneal donor pool of tissue without ASF will, in part, be reduced by the increasing popularity of corneal refractive procedures. Already, it is estimated that approximately 2% of tissue received by the Lions Eye Bank of Oregon cannot be used in PK as a result of previous corneal refractive procedures and this number should only increase in the near future. Additionally, as a result of the rapid recovery and quality outcomes from DSAEK, surgeons are operating on patients with better vision and less severe disease, which means there will be an increase in the overall number of surgeries performed and a rise in the demand for tissue. This, coupled with a higher primary graft failure rate in DSAEK than in PK, found especially with novice surgeons using certain surgical techniques, will lead to increased rates of repeat grafting and may severely diminish donor tissue availability in the near future.
In 2007, Armour et al reported the safe use of tissue in deep lamellar endothelial keratoplasty that was deemed unacceptable for use in PK surgery. 20 Since March 2000, our center has performed .800 EK procedures (either deep lamellar endothelial keratoplasty or Descemet's stripping endothelial keratoplasty/DSAEK) and in that prospective series, we have accepted ASF donor tissue for transplantation, which would have previously gone unused.
Recently, DSAEK has gained wide acceptance. With this in mind, we have now reviewed all of our cases of DSAEK using ASF donor tissue. We have retrospectively reviewed our prospectively obtained results using this tissue and compared the results with a time-matched control group of consecutive DSAEK eyes using standard tissue. The objective of this study was to determine the safety and effectiveness of using microkeratome cut ASF tissue for use in DSAEK surgery.
METHODS
Institutional Review Board approval was obtained through our hospital for our clinical protocol. An investigational surgical consent form for 5-mm incision DSAEK surgery was approved. DSAEK was then performed and postoperative data were gathered on patients in a prospective, consecutive, nonrandomized series.
A retrospective chart review was performed on this prospective series to determine which DSAEK surgeries were performed using ASF donor tissue. The database of the Lions Eye Bank of Oregon was reviewed to find donors that had been used in our DSAEK series that had anterior pathology such as pterygia inside the 8-mm zone, stromal scars, and refractive procedures and had been designated by the medical director as acceptable for endothelial transplant but unusable for PK. We found 42 eyes meeting these criteria. Preoperative and postoperative results of this study group were compared with a control group consisting of the 357 time-matched controls receiving standard donor corneas. Demographic data, including age, sex, and underlying eye diseases, were compared between the 2 groups. Pre-and postoperative evaluation for both groups included Snellen best spectacle-corrected visual acuity (BSCVA), manifest refraction, astigmatism, corneal topographic quality as measured by surface regularity index (SRI) and surface asymmetry index (SAI), and keratometry. Additionally, postoperative complications, including rejection episodes, noted to have occurred at or before the 6-month protocol visit were documented. Further details on the methodology of data acquisition is documented in our previous publications. 2, 14 Eyes with comorbidities such as retinal pathology were not excluded from analysis.
Surgical Procedure
All patients underwent 5.0-mm scleral incision DSAEK by one experienced surgeon (M.A.T.) and 5 novice surgeons (K.H., E.C., N.S., P.P.) from September 2005 to February 2008. The 5.0-mm incision surgical procedure and instrumentation are well described in previous reports. 2, 14 When prepared intraoperatively, the donor tissue in this DSAEK series was prepared by the surgeons cutting the tissue with a Moria microkeratome and artificial anterior chamber system (AAC; Moria Systems, Doylestown, PA) always using a 300-mm head, and no pachymetry was performed before the resection. When precut by the eye bank, tissue was cut using an identical system, but the following protocol was used. Tissue thickness is predetermined with ultrasound pachymetry (DGH Pachette 2; DGH technology Inc., Exton, PA). If the tissue is known to have had previous LASIK or if the thickness is ,450 mm, then a 250-mm head is used to make the cut. If the tissue is between 451 and 499 mm, a 300-mm head is used and if the tissue is .500 mm, then a 350-mm head is used. The surgeon and the eye bank were consistent in their techniques of tissue preparation for both control and ASF donor tissue. When cut by the eye bank, the microkeratome cuts were all made successfully below the level of the LASIK flaps and other anterior pathology. The tissue preparation was consistent regardless of the presence of pterygium or anterior scarring, because these pathologies did not prevent creation of a good seal on the artificial anterior chamber. measurements to allow averaging and statistical analysis. Group comparisons were analyzed by an independent Student t test. Preoperative and postoperative comparisons within the 2 groups were analyzed by a paired t test.
RESULTS

Donor Tissue
The study donor group consisted of 42 corneas; however, one donor was perforated intraoperatively before insertion into the recipient and was replaced by standard tissue, leaving 41 eyes that underwent 5.0-mm incision DSAEK surgeries using ASF tissue. Figure 1 shows examples of 2 donor tissues used in the study group, one with radial keratotomy scars seen preinsertion and postinsertion and one LASIK tissue postcut before insertion. Of these study eyes, 19 had follow up of 6 months. Twenty-nine donors had anterior corneal scars or opacities. Two study corneas had a pterygium within the 8-mm zone, 7 had prior LASIK only, 2 had prior refractive keratoplasty only, and one had both refractive keratoplasty and LASIK ( Table 1 ). The control donor group consisted of 357 consecutive DSAEK surgeries beginning during the same time period performed using standard donor corneas that were suitable for PK.
Patient Demographics
Patient demographics were similar between the study and control groups ( Table 2) .
Tissue Cutting
The initial 10 ASF tissues and 219 control tissues were cut intraoperatively by the surgeon and the following 32 ASF tissues and 138 control tissues were delivered precut by the Lions Eye Bank of Oregon. There was one perforation of a surgeon-cut ASF tissue intraoperatively. The donor was designated ASF as a result of prior LASIK surgery. This one perforation occurred while using a 300-mm head without preresection pachymetry. This tissue was discarded before insertion and therefore not included in the postoperative analysis. No tissue in the control group was reported as damaged during intraoperative cutting (0% rate of tissue wastage).
Intraoperative Data
In the study group, concurrent procedures were as follows: 17 (41%) had concurrent phacoemulsification, 2 (5%) had an intraocular lens exchange with an anterior vitrectomy, one patient had a concurrent anterior vitrectomy, and one had an iridoplasty. For the control group patients, 189 (53%) had concurrent phacoemulsification, 8 (2%) had anterior vitrectomies with intraocular lens exchanges, 6 (2%) had concurrent intraocular lens exchange, 4 (1%) had concurrent anterior vitrectomies, 3 had iridoplasty (1%), and 4 (1%) had concurrent surface scraping. The presence of comorbidities such as retinal pathology did not exclude a patient from analysis (study group: 16 [39%]; control group:116 [32%]).
There were no significant patient differences between the study group versus control in the data collected on preoperative BSCVA (study 20 
Postoperative Complications
Postoperative data were available for 41 eyes that received ASF tissue. All eyes in this study group and 357 eyes in the control group had follow up of at least 1 month, whereas 19 in the ASF group and 199 in the control group had follow up of 6 months. There were no cases of primary graft failure or pupillary block in either group. Dislocation of the tissue into the anterior chamber occurred in 10 cases in our control group (2.8%) and one case in our ASF group (2.4%). All were successfully reattached with an air bubble. Eight cases in our control group (2.2%) and one case in our study group (5.2%) experienced a rejection episode.
Six-month Data
Postoperative parameters are provided in Table 3 . The average BSCVA improved in both groups; in the study group (Table 4 ). There was no statistically significant topographic difference between the 2 groups (study group: SRI = 0.55, SAI = 0.89, K = 43.09 D; control group: SRI = 0.62, SAI = 0.9, K = 43.49 D; SRI P = 0.499, SAI P = 0.97, K P = 0.362). Refractive astigmatism was similar between the groups (study, 1.11 D; control, 1.12 D; P = 0.964) as was pachymetry (study, 0.652 mm; control, 0.668 mm; P = 0.307). Finally, there was no difference in endothelial cell density between the groups at 6 months (study 1975 cells/ mm 2 versus control 1907 cells/mm 2 ; P = 0.571) and, more importantly, in cell loss from preoperative to postoperative (study 32% cell loss versus control 33% cell loss; P = 0.714).
DISCUSSION
As the ''baby boomer'' population ages and life expectancy increases, the demand for donor corneal tissue may increase. Simultaneously, an ever increasing segment of the population is undergoing refractive surgery leading to an expected decrease in the supply of acceptable tissue for PKs. With these pressures on already stressed eye banks, the demand for healthy donor tissue may begin to overwhelm the supply. With this foresight, the medical advisory board of the EBAA has allowed the use of tissue with good endothelial cell densities, but with anterior pathology, to be used in EK surgery. 1 A review, by one of the authors (C.S.), of donor tissue collected by the Lions Eye Bank of Oregon during the same time period as our study leads to estimates that approximately 6% of additional tissue has now become available for EK surgery. Nearly one third of this tissue was designated as ASF tissue as a result of previous refractive procedures such as refractive keratoplasty, photorefractive keratectomy, and LASIK. Before this designation, this tissue would have been unavailable for transplantation.
At the Lion's Eye Bank of Oregon, where precutting of donors is performed, the tissue is evaluated postresection by certified eye bank technicians for damage in the form of uneven cuts, signs of endothelial cell loss or damage, and other abnormalities. Although at this time, there is no set protocol to determine the appropriate postresection thickness of tissue and tissue has been distributed from the Lion's Eye Bank for use in EK as thin as 99 mm and as thick as 265 mm, tissue outside this range might also be discarded at the discretion of the certified eye bank technician or the medical director. When it is determined that postresection tissue is damaged, it is discarded. Evaluation of damaged tissue is logged in the eye bank database. A review of this database during the same time period as our study revealed that there were no full-thickness perforations resulting from cutting 89 ASF tissues and 1043 standard tissues. There were 19 standard tissues (1.8%) and 2 ASF tissues (2.2%) reported as damaged, however. The damage to the 2 ASF tissues occurred during dismounting the tissues and not during the actual cutting; therefore, no damage to ASF 34% male (n = 14) 66% female (n = 27) 37% male (n = 132) 63% female (n = 225) Reason for transplant 71% Fuchs (n = 29) 24% PBK (n = 10) 5% other endothelial dysfunction (n = 2) 80% Fuchs (n = 285) 14% PBK (n = 51) 6% other endothelial dysfunction (n = 22)
ASF, anterior stromal flawed; PBK, pseudophakic bullous keratopathy. tissue resulted from the pass of the microkeratome blade, arguably the step of greatest concern when cutting ASF tissue. Similarly, of the 19 damaged standard tissues, 5 (0.5%) were damaged during this cutting step, with other damage occurring during mounting or dismounting the tissue from the anterior chamber or from unknown causes.
It is important to address the one episode of perforation of ASF tissue that occurred during intraoperative cutting by the surgeon. Before converting to the use of solely precut tissue at our center, the donors were all cut intraoperatively using a standard 300-mm microkeratome head without the use of ultrasound pachymetry. We now believe that such a method of indiscriminately cutting all tissue with a 300-mm head does not safeguard a surgeon against the undesired complication of tissue perforation. We do feel that intraoperative cutting of tissue can be safely performed, however, if the surgeon knows the corneal thickness and modifies the depth of cut appropriately as is the procedure followed by technicians at the Lions Eye Bank of Oregon. Although knowing the corneal thickness and modifying the microkeratome depth can avoid unnecessary perforation of tissue, it may not be feasible to cut tissue that is excessively thin (,350 mm) from pathology or previous high myopic laser correction. Additionally, it is understood that anterior stromal flaws should be anterior to the depth of the expected microkeratome cut to ensure no central imperfections remain in the donor tissue. When cutting is performed before surgery at an eye bank, the tissue is also checked post cut to be certain that the donor is of appropriate thickness and without flaws.
Although it has been reported previously that ASF tissue can be safely used in deep lamellar endothelial keratoplasty surgery 20 and the assumption has been made that it would also be safe and effective in DSAEK, in which tissue cutting is ''automated'' with the use of a microkeratome, there have been no data previously published to confirm this. Possible concerns about using ASF tissue in DSAEK might be that the rate of dislocations and primary graft failures would increase with its use. Other concerns include that surface irregularities from scarred donor tissue might be transferred to the bed of the transplanted stromal donor interface from microkeratome preparation or that refractive topography from donors with previous high myopic excimer laser treatment might transfer from the surface to the donor interface and affect refractive outcomes. Armour et al did not find any evidence of these concerns when using ASF tissue in deep lamellar endothelial keratoplasty surgery. 20 They also pointed out that there is a significantly muted contribution of the posterior cornea to the overall refraction of the eye making it very unlikely that even high myopic laser treatments would transfer to affect refractive outcome. Our results using ASF tissue in DSAEK surgery now demonstrate this more clearly and it appears that transfer of such optical irregularities or refractive indices from the donor surface to the interface, if it occurs, does not affect the expected postoperative topographies, refractive outcomes, or BSCVA. This retrospective review of our prospective data on 41 eyes undergoing DSAEK receiving tissue unacceptable for PK confirms both the safety and effectiveness of its use with no increase in dislocations or primary graft failures and the equivalent BSCVA, refractive, and topographic results to those found in DSAEK with standard donor tissue. We have also demonstrated, as might be anticipated, the equivalency of 6-month endothelial cell densities between these populations. DSAEK surgery is now viewed by most as the new standard of care for the treatment of endothelial failure. With early recovery of high-quality visual acuity, most corneal surgeons have converted to this exciting new technique. However, many surgeons, both novice and experienced, have had very high complication rates with high rates of dislocations and even more alarming high rates of primary graft failure 18, 21, 22 leading to the loss of precious corneal tissue. Although previous studies by Chen et al 19 have shown no clear association between donor tissue characteristics and surgical results, some surgeons may blame high dislocation and primary graft failures rates on the perceived quality of tissue they are receiving. There is a growing demand on eye banks for ''perfect'' tissue with higher endothelial cell counts than what has previously been requested for PK. 21, 23 We have demonstrated that imperfect tissue with ''flawed'' anterior stroma can be safely and effectively used for EK surgery even with automated preparation of the tissue using a microkeratome.
Continued prospective data collection is ongoing at our center and will most likely continue to affirm our assertion that the use of tissue that is unacceptable for PK but has healthy endothelium is not only reasonable, but may be necessary to help meet the increasing demands for corneal transplant tissue. The collection of prospective data with continued careful evaluation of outcomes is the preferred course, which will guide us to the most definitive answers. 
